New RNA drug ORN252 tested in humans for first time

NCT ID NCT07439796

Recruiting now Knowledge-focused Sponsor: Orna Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study is testing a new experimental drug called ORN252 in 20 healthy adults. ORN252 is a type of RNA therapy wrapped in a fat particle, designed to help the body make a protein that targets certain immune cells. The main goal is to check if it is safe and how the body handles it. This is a first step and does not aim to treat any disease yet.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ORN252 (a lipid nanoparticle containing circular RNA that encodes a CAR protein targeting CD19)
What this could lead to: If safe, this could pave the way for future studies of ORN252 as a potential cancer therapy.
What could go wrong: This is a very early, small phase 1 trial in healthy people, not patients. It only tests safety and how the drug moves through the body, not whether it works against any disease. Side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS - MALE AND FEMALE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS - MALE AND FEMALE

Contacts and locations

Locations

Nucleus Network
RECRUITING

Herston, Queensland, 4006, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.